

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Shanghai HeartCare Medical Technology
Corporation Limited**

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

**PROPOSED ISSUE OF A SHARES AND
LISTING ON THE SCI-TECH BOARD OF
THE SHANGHAI STOCK EXCHANGE
AND**

PROPOSED AMENDMENT OF THE ARTICLES

**PROPOSED ISSUE OF A SHARES AND LISTING ON THE SCI-TECH
BOARD OF THE SHANGHAI STOCK EXCHANGE**

The board (the “**Board**”) of directors of Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”) is pleased to announce that the Board proposed to apply to the relevant regulatory authorities in the PRC for the allotment and issue of not more than 7,025,592 A shares (the “**A Shares**”) of the Company (the “**Issue of A Shares**”) and proposed to apply to the Shanghai Stock Exchange for the listing of, and permission to deal in, the A Shares on the Sci-Tech Board.

The Issue of A Shares will be subject to, among other things, the approval by the shareholders of the Company (the “**Shareholders**”) by way of special resolutions at an upcoming extraordinary shareholders’ general meeting of the Company (the “**EGM**”), as well as the approvals by the China Securities Regulatory Commission (the “**CSRC**”) and the Shanghai Stock Exchange.

PROPOSED AMENDMENT TO THE ARTICLES

In order to prepare for the proposed Issue of A Shares and listing on the Sci-Tech Board and comply with the relevant CSRC and Shanghai Stock Exchange rules, to further improve and regulate the articles of association of the Company (the “**Articles**”) and to satisfy the relevant requirements of laws, regulations and regulatory documents, including the

Company Law of the PRC (《中華人民共和國公司法》), the Guidelines for Articles of Association of Listed Companies (《上市公司章程指引》) and the Rules Governing the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange (《上海證券交易所科創板股票上市規則》), to bring its existing Articles to be in line with the relevant requirements of the applicable laws of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), in particular Appendix 3 to the Listing Rules regarding the core shareholder protection standards which became effective on January 1, 2022, to make other miscellaneous and housekeeping changes, and taking the practical circumstances of the Company into consideration, the Board resolved to amend the existing Articles.

A circular containing, among other things, the above matters and a notice of the EGM will be despatched to the Shareholders in due course.

There is no assurance that the proposed Issue of A Shares will proceed. Shareholders and investors are advised to exercise caution in dealings in the shares of the Company. Further details about the proposed issue of A Shares will be disclosed by the Company in due course.

By Order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, August 14, 2026

As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.